anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and systems are described for providing output based on detection of anxiety in a subject. Output is provided, dependent on an anxiety indication that represents a current or expected level of anxiety in the subject. A  physiological signal is received, representing physiological information from the subject. A    context signal is also received. A user state detector determines a current user state from a plurality of possible user states, based on the context signal.  An interactive multiple model (IMM) filter is used to determine, using the physiological signal, a statistical prediction of anxiety in each of the possible user states. An anxiety detector is used to output the anxiety indication, based on a weighting of the statistical predictions using the determined current user state.
Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
Participants receive a Formulation C starting dose of VH4524184 LAI subcutaneously. This intervention is optional and initiated only if Formulation B is poorly tolerated.
The study will evaluate the efficacy and safety of aiTBS in unipolar and bipolar depressive patients with NSSI or suicidal thoughts and behaviors by measuring changes in clinical ratings at baseline, after all the treatments, and 2 weeks, 4 weeks after treatment. 60 inpatients will be randomized to receive active or sham interventions administered to the left dorso-lateral prefrontal cortex. The treatment will apply active aiTBS rTMS involving 1800 pulses (9 minutes), 5x daily at 60 minutes intervals for 5 days. Changes in mood and sleep from baseline to the end of the study will be measured with The Hamilton Rating Scale for Depression-17 item (HAM-D17), Hamilton Anxiety Scale (HAMA), Young's Mania Scale (YMRS), and Pittsburgh Sleep Quality Index (PSQI) . Non-suicidal self injury will be assessed by the Deliberate Self-Harm Inventory (DSHI) and the Ottawa self-injury inventory (OSI). Suicidal ideation and behaviors assessments include Beck Suicidal Scale Inventory (BSI), the Ottawa self-injury inventory (OSI) and several questions from Self-Injurious Thoughts and Behaviors Interview - Revised (SITBI-R). Improvement of cognitive dysfunction could be measured by Barratt Impulsiveness Scale-11 (BIS-11), near infrared spectroscopy (fNIRS). Treatment Emergent Symptom Scale (TESS) would be used to eliminate side effects of combined drugs at baseline and the adverse event record form (AERF) will be used to appraise the safety of aiTBS treatment using these parameters. To record the change in sensitivity to pain and examine the tolerability of the treatment for these participants, visual analogue scale (VAS) is employed after completing 5 sessions treatment every day.
Background and Objectives: Proximal junctional kyphosis (PJK) and failure (PJF), the most prevalent complications following long-segment thoracolumbar fusions for adult spinal deformity (ASD), remain lacking in defined preventive measures. We studied whether one of the previously reported strategies with successful results-a prophylactic augmentation of the uppermost instrumented vertebra (UIV) and supra-adjacent vertebra to the UIV (UIV + 1) with polymethylmethacrylate (PMMA)-could also serve as a preventive measure of PJK/PJF in minimally invasive surgery (MIS). Materials and Methods: The study included 29 ASD patients who underwent a combination of minimally invasive lateral lumbar interbody fusion (MIS-LLIF) at L1-2 through L4-5, all-pedicle-screw instrumentation from the lower thoracic spine to the sacrum, S2-alar-iliac fixation, and two-level balloon-assisted PMMA vertebroplasty at the UIV and UIV + 1. Results: With a minimum 3-year follow-up, non-PJK/PJF group accounted for fifteen patients (52%), PJK for eight patients (28%), and PJF requiring surgical revision for six patients (21%). We had a total of seven patients with proximal junctional fracture, even though no patients showed implant/bone interface failure with screw pullout, probably through the effect of PMMA. In contrast to the PJK cohort, six PJF patients all had varying degrees of neurologic deficits from modified Frankel grade C to D3, which recovered to grades D3 and to grade D2 in three patients each, after a revision operation of proximal extension of instrumented fusion with or without neural decompression. None of the possible demographic and radiologic risk factors showed statistical differences between the non-PJK/PJF, PJK, and PJF groups. Conclusions: Compared with the traditional open surgical approach used in the previous studies with a positive result for the prophylactic two-level cement augmentation, the MIS procedures with substantial benefits to patients in terms of less access-related morbidity and less blood loss also provide a greater segmental stability, which, however, may have a negative effect on the development of PJK/PJF.
The present invention relates to temperature controlled heat treatment embolism sponge particles. The temperature controlled heat treatment embolism sponge particles are composed of high molecular materials and magnetic responding particles contained in the high molecular materials, wherein the magnetic responding particles made of alloy materials at the curie temperature of 40 to 65 DEG C are scattered in a cross-linked network formed by the high molecular materials. The diameter of each heat treatment embolism sponge particle is from 50 to 2000 mu m, and the water absorption force of each heat treatment embolism sponge particle is not less than 5 times of the number of the particles. The magnetic responding particles account for 0.5 to 45% of the total embolism sponge particles in the proportion by weight. A preparing method of the present invention comprises the following steps of (1) synthesizing a sponge solidified object containing the magnetic responding particles and (2) preparing an embolism agent of the magnetic responding polymer particles. The present invention has the following beneficial effects that 1) the embolism agent of the particles has obvious water absorption expandability, irregular shape and stronger blood vessel wall adhesiveness so that the embolism agent of the particles is firmly fixed at the embolism position, and the clinic side effect caused by falling off can be easily avoided; 2) the embolism agent of the particles has a porous structure and obvious water absorption force so that local blood dehydration can make an embolism formed in the blood vessel, and consequently, the embolism effect of the present invention is enhanced.
ETHNOPHARMACOLOGICAL RELEVANCE: Abelmoschus manihot (L.) Medik. Seeds (AMS, སོ་མ་ར་ཛ།), a Tibetan classical herbal in China, are rich in flavonoids and phenolic glycosides compounds, such as quercetin and its derivatives. Moreover, it has been found to possess anti-rheumatoid arthritis (RA) effects. Nonetheless, its anti-RA mechanism is yet unknown.
AIM OF THE STUDY: This research aimed to examine the active ingredients of AMS as well as potential pharmacological mechanisms in AMS on RA.
MATERIALS AND METHODS: The ultra-performance liquid chromatography-electrospray ionization-tandem multistage mass spectrometry (UPLC-ESI-IT-MSn) technique was used to determine the primary chemical components of AMS that were responsible for the therapeutic effects on RA. In addition, 36 male Wistar rats weighing between 200 and 220 g were classified at random into six groups [normal control group, collagen-induced arthritis (CIA) group, methotrexate group (positive control, 1.05 mg/kg), AMS group (157.5 mg/kg, 315 mg/kg, 630 mg/kg)]. CIA rats were given AMS extract by intragastric administration for 28 days, and their ankles were photographed to observe the degree of swelling. Further, the arthritis score, paws swelling, and body weight changes of CIA rats were determined to observe whether AMS has any effect on RA, and synovial and cartilage tissue injuries were identified by histopathology. Besides, the levels of IL-10, TNF-α, IL-1β, INF-γ, etc. in serum were estimated by ELISA. Western blot experiments were implemented to identify the expression levels of protein involved in the JAK2/STAT3 signaling pathway in the CIA rats' synovial tissues. Moreover, the mechanisms and targets of active ingredient therapy of AMS for RA were predicted using network pharmacology and then verified using molecular docking.
RESULT: In the present study, 12 compounds were detected by UPLC-ESI-IT-MSn, such as quercetin and its derivative which could be potential active ingredients that contribute to the anti-RA properties of AMS. Our in vivo studies on CIA rats revealed that an AMS-H dose of 630 mg/kg significantly improved joint damage while decreasing the arthritic index and paw swelling. Furthermore, AMS inhibited the INF-γ, IL-6, IL-17, IL-1β, and TNF-α, levels while upregulating the expression of anti-inflammatory cytokines IL-10 and IL-4 in serum. Besides, AMS inhibited the protein Bcl-2/Bax, STAT3, and JAK2 levels, and promoted the expression of Caspase3, SOCS1, and SOCS3 in the JAK2/STAT3 pathway. Additionally, the JAK/STAT signaling pathway was found to perform a remarkable function in the AMS therapy of RA as evidenced by enrichment in GO terms and KEGG pathways. Meanwhile, data from molecular docking experiments indicated that the core targets of PIK3CA, JAK2, and SRC bound stably to the active ingredients of mimuone, 4'-methoxy-bavachromanol, and quercetin.
CONCLUSION: According to these findings, the AMS could improve joint inflammation in CIA rats, and its underlying mechanism could be linked to the regulation of the JAK2/STAT3 pathway. Therefore, AMS might become a promising agent for alleviating inflammation in RA patients.
The present invention relates to a method and systems for collecting and quantifying data from both the practitioner and the subject during a treatment, contact or manipulation. The present invention acquires data of the applied manipulation and central nervous system data prior, during and post manual therapy treatments targeting joints. The data is obtained using edge devices having sensors (e.g., accelerometers, magnetometers, gyroscopes, pressure sensors, force sensors, heart rate monitors, temperature sensors, blood oxygenation sensors, respiration sensors and the like). Examples of types of manipulation devices having edge devices include bracelets, headbands, body bands, bands, straps, rings, towels that are used by both the practitioner and the subject. The edge devices communicate wirelessly with a central hub to collect data. The hub is responsible for collecting, processing, storing and uploading data to the cloud. Within the cloud, data is further filtered, analyzed, organized and displayed on an interactive platform.
Safety and effectiveness of ABILIFY ASIMTUFII in pediatric patients have not been established. 

Juvenile Animal Studies

No juvenile animal studies were conducted with intramuscular aripiprazole suspension. A study with oral aripiprazole in juvenile rats caused mortality, CNS clinical signs, impaired memory and learning, and delayed sexual maturation when administered at doses of 10, 20, 40 mg/kg/day from weaning (21 days old) through maturity (80 days old). At 40 mg/kg/day, mortality, decreased activity, splayed hind limbs, hunched posture, ataxia, tremors and other CNS signs were observed in both genders. In addition, delayed sexual maturation was observed in males. At all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed. The changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. A No Observed Adverse Effect Level (NOAEL) could not be determined and, at the lowest tested dose of 10 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended oral pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies.

Aripiprazole in juvenile dogs (2 months old) caused CNS clinical signs of tremors, hypoactivity, ataxia, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. Mean body weight and weight gain were decreased up to 18% in females in all drug groups relative to control values. A NOAEL could not be determined and, at the lowest tested dose of 3 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended oral pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period.
In the KT group, a standard 2-inch (5 cm) Kinesio®Tex tape (Kinesio Holding Corporation, Albuquerque, New Mexico, USA) was used with techniques of muscle inhibition and fascia correction. Kinesio tape was applied once a week for four weeks.
Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
There is still a lack of knowledge, attitudes, practices, communication skills, and self-awareness among parents and teachers, so education is needed relating to the prevention of CSA. The need to educate parents and teachers is significant because parents are the first teachers of their children in sexual education. Involving parents in educating children about CSA will be effective in encouraging children to use self-protection skills, enabling children to increase safety in the home environment, communication between parents and their children about sexuality, and screening of caregivers. Parents and teachers are the essential sources of providing information to children. The use of media can affect increased knowledge. Several studies on preventing CSA have proven effective in preventing CSA, such as education using discussion methods, pictures, videos, puppets, and sketches.

Education programs regarding the prevention of CSA in schools need to be introduced and taught through schools by involving parents of students at home and teachers at schools, bearing in mind that currently, there is no specific educational program regarding the prevention of CSA in schools. Social media is the dominant communication tool in the 4.0 era. Support can be offered in schools through appropriate methods of preventing CSA due to its broad reach and impact on children's lives. The method is education on the prevention of CSA by using the Mobile Application for Prevention of CSA in Schools (MA_PESAN), which will be developed in this research. The MA_PESAN educational method is education that uses an application intended for parents of students and teachers. The content used in the MA_PESAN material contains material related to the prevention of CSA, the age of children to start being taught CSA prevention, who are the perpetrators/predators of CSA, whether the perpetrators are adults or fellow children, the importance of communication between parents and teachers and children, and eliminating cultural taboos in inform CSA that other studies in the contents of the research material have not carried out.
INTRODUCTION AND HYPOTHESIS: We compared postoperative complications in elderly patients discharged on POD#0 versus POD#1 after prolapse repair.
METHODS: Data were obtained from the National Surgical Quality Improvement database. A total of 20,984 women 65 years and older who underwent prolapse repair between 2014 and 2020 were analyzed. Patient demographics, comorbidities, readmission, reoperation, and 30-day postoperative complications were compared in patients discharged on POD#0 versus POD#1. A sensitivity analysis was completed to examine outcomes in patients who underwent an apical prolapse repair. Multivariate logistic regression was performed to evaluate for potential confounders.
RESULTS: Age, race, ethnicity, American Society of Anesthesiologists class, prolapse repair type, and operative time were significantly different in patients discharged on POD#0 vs POD#1 (all p < 0.01). Patients discharged on POD#0 had significantly fewer postoperative complications (2.63% vs 3.44%) and readmissions (1.56% vs 2.18%, all p < 0.01). On multivariate regression modeling, postoperative discharge day was independently associated with complications, but not with readmissions or reoperation after. Patients who underwent an apical prolapse repair and were discharged on POD#0 had significantly more postoperative complications (3.5% vs 2.5%, p = 0.02) and readmissions (2.42% vs 10.08%, p < 0.01) than those discharged on POD#1. In this group, multivariate regression modeling demonstrated that postoperative discharge day was independently associated with any postoperative complication.
CONCLUSIONS: For elderly women undergoing prolapse repair, the type of surgery should be considered when determining postoperative admission versus same-day discharge. Admission overnight does not seem to benefit women undergoing vaginal repairs but may decrease overall morbidity and risk of readmission in women undergoing an apical prolapse repair.
UNLABELLED: Therapy resistance and metastatic progression are primary causes of cancer-related mortality. Disseminated tumor cells possess adaptive traits that enable them to reprogram their metabolism, maintain stemness, and resist cell death, facilitating their persistence to drive recurrence. The survival of disseminated tumor cells also depends on their ability to modulate replication stress in response to therapy while colonizing inhospitable microenvironments. In this study, we discovered that the nuclear translocation of AXL, a TAM receptor tyrosine kinase, and its interaction with WRNIP1, a DNA replication stress response factor, promotes the survival of HER2+ breast cancer cells that are resistant to HER2-targeted therapy and metastasize to the brain. In preclinical models, knocking down or pharmacologically inhibiting AXL or WRNIP1 attenuated protection of stalled replication forks. Furthermore, deficiency or inhibition of AXL and WRNIP1 also prolonged metastatic latency and delayed relapse. Together, these findings suggest that targeting the replication stress response, which is a shared adaptive mechanism in therapy-resistant and metastasis-initiating cells, could reduce metachronous metastasis and enhance the response to standard-of-care therapies.
SIGNIFICANCE: Nuclear AXL and WRNIP1 interact and mediate replication stress response, promote therapy resistance, and support metastatic progression, indicating that targeting the AXL/WRNIP1 axis is a potentially viable therapeutic strategy for breast cancer.
This is a phase 1-2 randomized, double-blind, sham-controlled, multiple-ascending dose (MAD) study to evaluate ION440 in pediatric and adult participants with MECP2 Duplication Syndrome (MDS) and will be conducted in two parts. During Part 1 (MAD) (36 weeks), participants will be randomized in a 3:1 ratio to receive ION440 or sham. Individuals who complete Part 1 may enter Part 2, an open label long-term extension study (LTE), where they will receive ION440 for up to approximately 156 weeks. Multiple dose cohorts (Dose A, Dose B, and Dose C) will be evaluated in the study.

All dosing cohorts will be further subdivided by age. Sub cohort A will include participants 8 years of age and older and sub cohort B will include participants 2 through 7 years of age. Dosing cohorts will be enrolled sequentially with sub cohort A initiating prior to sub cohort B.
The present invention refers to a herbal remedy based on an aqueous solution of Cydonia oblonga with an anti-inflammatory, analgesic, healing and mucoprotector effect, characterised as: finished product, process for the manufacture and application thereof. As a finished product it is a water soluble composition 1/10 (w/v) of a medicinal extract obtained from the aerial parts of a plant commonly known as quinces which scientific name is: Cydonia oblonga recognised with the name of Pavardo Solution. As a manufacturing process includes the decoction of the aerial parts of the plants for two hours, which results in a final composition of approximately 10% of the vegetable material in water, without preservatives and additives, which has a pH of 6.0, complies with the microbiological standards of being an innocuous preparation presented in darkened crystal containers. As an application process, the invention includes a multipurpose solution, depending on the treatment, such as: 1. a liquid product orally administered, with analgesic and mucoprotector effect. 2. As a liquid product in a spray form, moistened dressings or patches applied in enough and constant amounts in external surfaces with I and III degree burns, eczema, or other skin or vascular lesions, useful for relieving pain, obtaining anti-inflammatory and antiseptic effects and tissue regeneration, which promote the healing of the lesions over days depending on the intensity of the damage.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to a medicinal form as suppository containing erythromycin. Drug has erythromycin and a base - solid confectionery fat on the basis of plasticized hydrogenated fat or "Vitepsol" at the following content of components, g/suppository (mass is 1.15-1.40 g): erythromycin 0.4-0.12, and a base - the rest. Invention provides high therapeutic effectiveness, maximal concentration of blood erythromycin is occurred in 120-135 min. An agent shows high antibacterial effect. The proposed drug shows high stability at storage and retains physical-chemical properties for 2-2.5 years without alternations. EFFECT: enhanced effectiveness of an agent. 2 tbl